Modulation of immunostimulatory properties of oligonucleotide-based compounds by utilizing modified immunostimulatory dinucleotides
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
C07H-021/02
C07H-021/04
A01N-043/04
A61K-031/70
출원번호
US-0952863
(2010-11-23)
등록번호
US-8153608
(2012-04-10)
발명자
/ 주소
Agrawal, Sudhir
Bhagat, Lakshmi
Yu, Dong
Kandimalla, Ekambar R.
출원인 / 주소
Idera Pharmaceuticals, Inc.
대리인 / 주소
Wood, Phillips, Katz, Clark & Mortimer
인용정보
피인용 횟수 :
4인용 특허 :
21
초록▼
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end.
대표청구항▼
1. A method for therapeutically treating a patient having a disease or disorder, such method comprising administering to the patient an immunomer having the structure selected from 5′-CTGTC1GTTCTC-X-CTCTTGC1TGTC-5′ (5′-SEQ ID NO: 177-3′-X-3′-SEQ ID NO: 177-5′); 5′-TC1GTC1GTTCTG-X-GTCTTGC1TGC1T-5′ (5
1. A method for therapeutically treating a patient having a disease or disorder, such method comprising administering to the patient an immunomer having the structure selected from 5′-CTGTC1GTTCTC-X-CTCTTGC1TGTC-5′ (5′-SEQ ID NO: 177-3′-X-3′-SEQ ID NO: 177-5′); 5′-TC1GTC1GTTCTG-X-GTCTTGC1TGC1T-5′ (5′-SEQ ID NO: 181-3′-X-3′-SEQ ID NO: 181-5′); 5′-TCTGTC1GTTCT-X-TCTTGC1TGTCT-5′ (5′-SEQ ID NO: 170-3′-X-3′-SEQ ID NO: 170-5′); 5′-TCG1TCG1TTCTG-X-GTCTTG1CTG1CT-5′ (5′-SEQ ID NO: 172-3′-X-3′-SEQ ID NO: 172-5′); and 5′-CTGTCG2TTCTC-X-CTCTTG2CTGTC-5′ (5′-SEQ ID NO: 171-3′-X-3′-SEQ ID NO: 171-5′); wherein X is a glycerol linker, C1 is 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine, G1 is 2′-deoxy-7-deazaguanosine and G2 is arabinoguanosine. 2. The method according to claim 1 wherein the disease or disorder to be treated selected from cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma and a disease caused by a pathogen. 3. The method of claim 1 further comprising administering a vaccine. 4. The method of claim 3, wherein the immunomer is linked to an immunogenic protein. 5. The method of claim 3 further comprising administering an adjuvant. 6. The method according to claim 1, further comprising administering a therapeutic agent selected from antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, peptides, proteins, gene therapy vectors, DNA vaccines, adjuvants, antigens and chemotherapeutic agents. 7. A method for the prophylactic treatment of a patient to prevent the onset of a disease or disorder, such method comprising administering to the patient an immunomer having the structure selected from 5′-CTGTC1GTTCTC-X-CTCTTGC1TGTC-5′ (5′-SEQ ID NO: 177-3′-X-3′-SEQ ID NO: 177-5′); 5′-TC1GTC1GTTCTG-X-GTCTTGC1TGC1T-5′ (5′-SEQ ID NO: 181-3′-X-3′-SEQ ID NO: 181-5′); 5′-TCTGTC1GTTCT-X-TCTTGC1TGTCT-5′ (5′-SEQ ID NO: 170-3′-X-3′-SEQ ID NO: 170-5′); 5′-TCG1TCG1TTCTG-X-GTCTTG1CTG1CT-5′ (5′-SEQ ID NO: 172-3′-X-3′-SEQ ID NO: 172-5′); and 5′-CTGTCG2TTCTC-X-CTCTTG2CTGTC-5′ (5′-SEQ ID NO: 171-3′-X-3′-SEQ ID NO: 171-5′); wherein X is a glycerol linker, C1 is 1-(2′-deoxy-β-D-ribofuranosyl)-2-oxo-7-deaza-8-methylpurine, G1 is 2′-deoxy-7-deazaguanosine and G2 is arabinoguanosine. 8. The method according to claim 7 wherein the disease or disorder selected from cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, skin disorders, allergy, asthma and a disease caused by a pathogen. 9. The method of claim 7 further comprising administering a vaccine. 10. The method of claim 9, wherein the immunomer is linked to an immunogenic protein. 11. The method of claim 9 further comprising administering an adjuvant. 12. The method according to claim 11, further comprising administering a therapeutic agent is selected from antibodies, cytotoxic agents, allergens, antibiotics, antisense oligonucleotides, peptides, proteins, gene therapy vectors, DNA vaccines, adjuvants, antigens and chemotherapeutic agents.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (21)
Agrawal Sudhir ; Habus Ivan ; Kandimalla Ekambar R., Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides.
Adrian Christopher Simmonds GB; Alan Hamilton GB; Clifford Smith GB; David Loakes GB; Daniel Brown GB; Fergal Hill GB; Shiv Kumar ; Satyam Nampalli ; Mark McDougall, Base analogues.
Froehler Brian (Belmont CA) Matteucci Mark (Burlingame CA), Enhanced triple-helix and double-helix formation with oligomers containing modified purines.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Pederson Thoru (Worcester MA) Agrawal Sudhir (Shrewsbury MA) Mayrand Sandra (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Method of site-specific alteration of RNA and production of encoded polypeptides.
Agrawal,Sudhir; Kandimalla,Ekambar R.; Yu,Dong; Bhagat,Lakshmi, Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends.
Agrawal,Sudhir; Kandimalla,Ekambar R.; Yu,Dong; Bhagat,Lakshmi, Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends.
Agrawal Sudhir (Shrewsbury MA) Zamecnik Paul C. (Shrewsbury MA), Process for synthesizing oligonucleotides and their analogs adaptable to large scale syntheses.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.